Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.55 |
| ▸ | ACE | P12821 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 6/20 | 0.49 |
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 5/20 | 0.46 |
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12568266 | 0.87 | PTPN1 (0.55) | SCN9AACEPTPN1PPARAPPARG | |
| SCHEMBL6170513 | 0.85 | ACE (0.57) | SCN9AACEPTPN1PPARAPPARG | |
| SCHEMBL503474 | 0.85 | ACE (0.57) | SCN9AACEPTPN1PPARAPPARG | |
| SCHEMBL1310039 | 0.83 | PTPN1 (0.53) | SCN9AACEPTPN1PPARAPPARG | |
| SCHEMBL8650372 | 0.83 | SCN9A (0.52) | SCN9AACEPTPN1PPARAPPARG | |
| SCHEMBL16448036 | 0.83 | PPARA (0.52) | SCN9AACEPTPN1PPARAPPARG | |
| SCHEMBL8650368 | 0.83 | SCN9A (0.52) | SCN9AACEPTPN1PPARAPPARG | |
| SCHEMBL16448238 | 0.82 | PTPN1 (0.55) | SCN9AACEPTPN1PPARAPPARG | |
| SCHEMBL28956926 | 0.80 | PTPN1 (0.54) | SCN9AACEPTPN1PPARAPPARG | |
| SCHEMBL3925164 | 0.80 | ACE (0.55) | SCN9AACEPTPN1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455539-B2 | AUTOIMMUNE DISEASE; ANTIINFLAMMATORY AGENTS; ANTIPROLIFERATORY AGENTS | CELLTECH R&D LIMITED (GB) | 2002-09-24 | — | — | US | disclosed |
| US-20010020017-A1 | Squaric acid derivatives | CELLTECH R&D LIMITED (GB) | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020017-A1 | Squaric acid derivatives | SUCNR1, HCAR1, CCR1 | SCN9A 1353/4885ACE 2696/4885PTPN1 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.